Diabetes Remission Status During Seven-year Follow-up of the Longitudinal Assessment of Bariatric Surgery Study
- PMID: 33270130
- PMCID: PMC7947785
- DOI: 10.1210/clinem/dgaa849
Diabetes Remission Status During Seven-year Follow-up of the Longitudinal Assessment of Bariatric Surgery Study
Abstract
Context: Few studies have examined the clinical characteristics that predict durable, long-term diabetes remission after bariatric surgery.
Objective: To compare diabetes prevalence and remission rates during 7-year follow-up after Roux-en-Y gastric bypass (RYGB) and laparoscopic gastric banding (LAGB).
Design: An observational cohort of adults with severe obesity recruited between 2006 and 2009 who completed annual research assessments for up to 7 years after RYGB or LAGB.
Setting: Ten US hospitals.
Participants: A total sample of 2256 participants, 827 with known diabetes status at both baseline and at least 1 follow-up visit.
Interventions: Roux-en-Y gastric bypass or LAGB.
Main outcome measures: Diabetes rates and associations of patient characteristics with remission status.
Results: Diabetes remission occurred in 57% (46% complete, 11% partial) after RYGB and 22.5% (16.9% complete, 5.6% partial) after LAGB. Following both procedures, remission was greater in younger participants and those with shorter diabetes duration, higher C-peptide levels, higher homeostatic model assessment of β-cell function (HOMA %B), and lower insulin usage at baseline, and with greater postsurgical weight loss. After LAGB, reduced HOMA insulin resistance (IR) was associated with a greater likelihood of diabetes remission, whereas increased HOMA-%B predicted remission after RYGB. Controlling for weight lost, diabetes remission remained nearly 4-fold higher compared with LAGB.
Conclusions: Durable, long-term diabetes remission following bariatric surgery is more likely when performed soon after diagnosis when diabetes medication burden is low and beta-cell function is preserved. A greater weight-independent likelihood of diabetes remission after RYGB than LAGB suggests mechanisms beyond weight loss contribute to improved beta-cell function after RYGB.Trial Registration clinicaltrials.gov Identifier: NCT00465829.
Keywords: beta-cell function; diabetes; gastric bypass; laparoscopic gastric band; remission.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
Comment in
-
Diabetes Remission After Gastric Bypass: To Be or Not to Be Dependent on Weight Loss.J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2362-e2364. doi: 10.1210/clinem/dgab008. J Clin Endocrinol Metab. 2021. PMID: 33524103 Free PMC article. No abstract available.
References
-
- Sjöström L, Narbro K, Sjöström CD, et al. ; Swedish Obese Subjects Study . Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752. - PubMed
-
- Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316–323. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
- R01 DK103842/DK/NIDDK NIH HHS/United States
- U01 DK066555/DK/NIDDK NIH HHS/United States
- UL1 RR024153/RR/NCRR NIH HHS/United States
- UL1 RR024996/RR/NCRR NIH HHS/United States
- U01 DK066585/DK/NIDDK NIH HHS/United States
- U01 DK066526/DK/NIDDK NIH HHS/United States
- M01 RR000037/RR/NCRR NIH HHS/United States
- UL1 TR002384/TR/NCATS NIH HHS/United States
- U01 DK066667/DK/NIDDK NIH HHS/United States
- U01 DK066471/DK/NIDDK NIH HHS/United States
- U01 DK066557/DK/NIDDK NIH HHS/United States
- U01 DK066568/DK/NIDDK NIH HHS/United States
- UL1 TR002369/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
